Comparison of OS by treatment assignment in patients with abnormal cytogenetics and with and without concurrent FLT3-ITD mutations. (A) OS from the time of treatment initiation in patients with AML aged ≥60 years with normal and abnormal cytogenetics by treatment type (IC vs HMA/VEN). (B) OS from the time of treatment initiation in patients with AML aged ≥60 years with and without concurrent FLT3-ITD mutations. Cyto, cytogenetics; MUT, mutant; WT, wild-type.